Investigating how a specific molecule affects brain damage after traumatic injury in mice
Role of Irg-1/itaconate in modulating secondary brain damage after traumatic brain injury in mice
This study is looking at how a natural molecule called itaconate might help protect the brain after a traumatic brain injury by calming down inflammation, and it's aimed at finding new ways to help people recover better from such injuries.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-11009954 on NIH RePORTER |
What this research studies
This research focuses on understanding how a molecule called itaconate, produced by the immune-responsive gene 1 protein, can help protect the brain after a traumatic brain injury (TBI). The study aims to explore how itaconate influences the behavior of inflammatory cells in the brain, potentially reducing harmful inflammation and preserving the integrity of the blood-brain barrier. By examining these processes in mice, researchers hope to uncover new therapeutic strategies that could improve recovery and long-term outcomes for individuals who have experienced TBI.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals who have suffered a traumatic brain injury and are experiencing secondary brain damage.
Not a fit: Patients with chronic brain injuries or those who do not have a recent traumatic brain injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce brain damage and improve recovery for patients with traumatic brain injuries.
How similar studies have performed: Other research has shown promise in targeting metabolic pathways to mitigate brain injury, suggesting that this approach could be a valuable addition to existing therapies.
Where this research is happening
New Orleans, United States
- Tulane University of Louisiana — New Orleans, United States (Active)
Researchers
- Principal investigator: Wang, Xiaoying — Tulane University of Louisiana
- Study coordinator: Wang, Xiaoying
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.